复发缓解型多发性硬化症的治疗进展与算法。
Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.
机构信息
Department of Neurology, Medical Faculty, University Hospital, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
出版信息
Neurotherapeutics. 2016 Jan;13(1):47-57. doi: 10.1007/s13311-015-0412-4.
Abstract
Treatment options in relapsing-remitting multiple sclerosis have increased considerably in recent years; currently, a dozen different preparations of disease-modifying therapies are available and some more are expected to be marketed soon. For the treating neurologist this broad therapeutic repertoire not only greatly improves individualized management of the disease, but also makes choices more complex and difficult. A number of factors must be considered, including disease activity and severity, safety profile, and patient preference. We here discuss the currently existing options and suggest treatment algorithms for managing relapsing-remitting multiple sclerosis.
摘要
近年来，复发缓解型多发性硬化症的治疗选择有了显著增加；目前，有十几种不同的疾病修正治疗制剂可供选择，预计不久还会有更多的制剂上市。对于治疗神经科医生来说，这种广泛的治疗方案不仅大大改善了疾病的个体化管理，而且使选择更加复杂和困难。有许多因素需要考虑，包括疾病的活动度和严重程度、安全性概况和患者偏好。我们在这里讨论了现有的选择，并为管理复发缓解型多发性硬化症提出了治疗方案。
相似文献
1
Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.复发缓解型多发性硬化症的治疗进展与算法。
Neurotherapeutics. 2016 Jan;13(1):47-57. doi: 10.1007/s13311-015-0412-4.
2
New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.美国食品药品监督管理局（FDA）新批准的用于治疗多发性硬化症的疾病修正疗法
Clin Ther. 2015 Apr 1;37(4):691-715. doi: 10.1016/j.clinthera.2015.03.001. Epub 2015 Apr 4.
3
Update on disease-modifying treatments for multiple sclerosis.多发性硬化症疾病修正治疗的最新进展。
Clin Ther. 2014 Dec 1;36(12):1938-1945. doi: 10.1016/j.clinthera.2014.08.006. Epub 2014 Sep 15.
4
Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.多发性硬化症门诊患者疾病修饰疗法对肿瘤发展的潜在风险及辅助因素。
Sci Rep. 2021 Jun 15;11(1):12533. doi: 10.1038/s41598-021-91912-x.
5
Update on disease-modifying therapies for multiple sclerosis.多发性硬化症疾病修正疗法的最新进展。
J Investig Med. 2017 Jun;65(5):883-891. doi: 10.1136/jim-2016-000339. Epub 2017 Jan 27.
6
Multiple sclerosis, a treatable disease .多发性硬化症，一种可治疗的疾病。
Clin Med (Lond). 2017 Dec;17(6):530-536. doi: 10.7861/clinmedicine.17-6-530.
7
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.在复发缓解型多发性硬化症中，与那他珠单抗、芬戈莫德和干扰素β相比，阿仑单抗的治疗效果：一项队列研究。
Lancet Neurol. 2017 Apr;16(4):271-281. doi: 10.1016/S1474-4422(17)30007-8. Epub 2017 Feb 11.
8
Pregnancy and Multiple Sclerosis: An Update on the Disease Modifying Treatment Strategy and a Review of Pregnancy's Impact on Disease Activity.妊娠与多发性硬化症：疾病修饰治疗策略的最新进展及妊娠对疾病活动影响的综述
Medicina (Kaunas). 2020 Jan 21;56(2):49. doi: 10.3390/medicina56020049.
9
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.BG-12（富马酸二甲酯）及其他疾病修正疗法治疗复发缓解型多发性硬化症的疗效与安全性：一项系统评价和混合治疗比较
Curr Med Res Opin. 2014 Apr;30(4):613-27. doi: 10.1185/03007995.2013.863755. Epub 2013 Nov 26.
10
Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.采用多准则决策分析（MCDA）评估克拉屈滨治疗复发缓解型多发性硬化症的获益风险。
Clin Ther. 2019 Feb;41(2):249-260.e18. doi: 10.1016/j.clinthera.2018.12.015.
引用本文的文献
1
Effect of autoimmune comorbidities on multiple sclerosis course: An observational multicenter study.自身免疫性合并症对多发性硬化病程的影响：一项多中心观察性研究。
Eur J Neurol. 2025 Jan;32(1):e70019. doi: 10.1111/ene.70019.
2
Human Umbilical Cord-Derived Mesenchymal Stem Cells in the Treatment of Multiple Sclerosis Patients: Phase I/II Dose-Finding Clinical Study.人脐带间充质干细胞治疗多发性硬化症患者的 I/II 期剂量探索临床研究。
Cell Transplant. 2024 Jan-Dec;33:9636897241233045. doi: 10.1177/09636897241233045.
3
The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing-Remitting Multiple Sclerosis.细胞基生物电子植入设备递送干扰素-β1a 疗法与注射用干扰素-β1a 治疗复发缓解型多发性硬化症的潜在成本效益比较。
Pharmacoeconomics. 2022 Jan;40(1):91-108. doi: 10.1007/s40273-021-01081-y. Epub 2021 Sep 4.
4
Innovative Medical Technology and the Treatment Decision-Making Process in Multiple Sclerosis: A Focus Group Study to Examine Patient Perspectives.创新医疗技术与多发性硬化症的治疗决策过程：一项聚焦小组研究以审视患者观点
Patient Prefer Adherence. 2021 May 7;15:927-937. doi: 10.2147/PPA.S306132. eCollection 2021.
5
Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment.血清神经丝轻链低值可识别多发性硬化症二甲基富马酸治疗的最佳应答者。
Sci Rep. 2021 Apr 29;11(1):9299. doi: 10.1038/s41598-021-88624-7.
6
An evaluation of the recognised systemic inflammatory biomarkers of chronic sub-optimal inflammation provides evidence for inflammageing (IFA) during multiple sclerosis (MS).对公认的慢性亚最佳炎症系统性炎症生物标志物的评估为多发性硬化症（MS）期间的炎症衰老（IFA）提供了证据。
Immun Ageing. 2021 Apr 14;18(1):18. doi: 10.1186/s12979-021-00225-0.
7
Role of Monoclonal Antibody "Alemtuzumab" in the Treatment of Multiple Sclerosis.单克隆抗体“阿仑单抗”在多发性硬化症治疗中的作用
Cureus. 2021 Feb 9;13(2):e13246. doi: 10.7759/cureus.13246.
8
Effectiveness of first-line treatment for relapsing-remitting multiple sclerosis in Brazil: A 16-year non-concurrent cohort study.巴西初治复发缓解型多发性硬化症的有效性：一项 16 年非同期队列研究。
PLoS One. 2020 Sep 2;15(9):e0238476. doi: 10.1371/journal.pone.0238476. eCollection 2020.
9
Interferons in the Treatment of Multiple Sclerosis: A Clinical Efficacy, Safety, and Tolerability Update.干扰素治疗多发性硬化症：临床疗效、安全性及耐受性最新进展
Int J MS Care. 2020 Jul-Aug;22(4):165-172. doi: 10.7224/1537-2073.2018-063. Epub 2019 Oct 30.
10
Regulatory B Cells Normalize CNS Myeloid Cell Content in a Mouse Model of Multiple Sclerosis and Promote Oligodendrogenesis and Remyelination.调节性 B 细胞可使多发性硬化症小鼠模型的中枢神经系统髓样细胞含量正常化，并促进少突胶质细胞生成和髓鞘再生。
J Neurosci. 2020 Jun 24;40(26):5105-5115. doi: 10.1523/JNEUROSCI.2840-19.2020. Epub 2020 May 19.
本文引用的文献
1
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.原发性进行性多发性硬化症的口服芬戈莫德（INFORMS）：一项 3 期、随机、双盲、安慰剂对照试验。
Lancet. 2016 Mar 12;387(10023):1075-1084. doi: 10.1016/S0140-6736(15)01314-8. Epub 2016 Jan 28.
2
PML: The Dark Side of Immunotherapy in Multiple Sclerosis.PML：多发性硬化症免疫治疗的阴暗面。
Trends Pharmacol Sci. 2015 Dec;36(12):799-801. doi: 10.1016/j.tips.2015.09.006. Epub 2015 Oct 21.
3
Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.那他珠单抗相关进行性多灶性白质脑病风险的分层与监测：专家组建议
J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):117-25. doi: 10.1136/jnnp-2015-311100. Epub 2015 Oct 22.
4
Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis.多发性硬化症患者发生进行性多灶性白质脑病的风险。
Expert Opin Drug Saf. 2015;14(11):1737-48. doi: 10.1517/14740338.2015.1093620. Epub 2015 Sep 22.
5
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.那他利珠单抗停药后，芬戈莫德对比干扰素β/那他珠单抗治疗多发性硬化症的疗效。
Brain. 2015 Nov;138(Pt 11):3275-86. doi: 10.1093/brain/awv260. Epub 2015 Sep 11.
6
Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod.用芬戈莫德治疗的多发性硬化症患者发生播散性隐球菌病。
Neurology. 2015 Sep 15;85(11):1001-3. doi: 10.1212/WNL.0000000000001929. Epub 2015 Aug 19.
7
Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis--Report of Two Cases.利妥昔单抗治疗多发性硬化症并发李斯特菌性脑膜炎——两例报告
Int J Mol Sci. 2015 Jun 29;16(7):14669-76. doi: 10.3390/ijms160714669.
8
Aggressive multiple sclerosis: proposed definition and treatment algorithm.侵袭性多发性硬化症：建议的定义和治疗算法。
Nat Rev Neurol. 2015 Jul;11(7):379-89. doi: 10.1038/nrneurol.2015.85. Epub 2015 Jun 2.
9
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.从那他珠单抗转换为芬戈莫德：一项针对复发缓解型多发性硬化症的随机、安慰剂对照研究。
Neurology. 2015 Jul 7;85(1):29-39. doi: 10.1212/WNL.0000000000001706. Epub 2015 May 29.
10
Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis.母体和父体在治疗复发缓解型多发性硬化症期间接触特立氟胺后的妊娠结局。
Neurol Ther. 2014 Nov 20;3(2):133-8. doi: 10.1007/s40120-014-0020-y. eCollection 2014 Dec.
Zotero 插件